UK-based biotech using AI-driven generative design and in-house labs to discover therapeutic-grade antibodies against traditionally undruggable targets such as GPCRs, ion channels and extracellular CFTR regions.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| $9.3 M | Mar, 2026 | series-a |
Frequently Asked Questions
Where is Antiverse located?
Antiverse is located in Cardiff, United Kingdom.
What industries does Antiverse operate in?
Antiverse operates in the following industries: biotechnology, therapeutics, antibody discovery, drug discovery, artificial intelligence.
When was Antiverse founded?
Antiverse was founded on 2026-03-03.
How much total funding has Antiverse raised?
Antiverse has raised a total of $9,300,000.
Who are the investors in Antiverse?
The investors in Antiverse are: Unspecified Lead Investor, Innovation Investment Capital, DOMiNO Ventures, DBW, Kadmos Capital, i&i Biotech Fund.
What is the main focus of Antiverse?
Antiverse is an AI-driven techbio company that specializes in the de novo design of therapeutic antibodies for challenging drug targets that are often considered undruggable by traditional methods.
Which types of drug targets is Antiverse designed to address?
The platform is specifically engineered to target complex membrane proteins such as G-protein coupled receptors (GPCRs), ion channels, and other transmembrane proteins that play critical roles in various diseases.
What is the typical timeline for Antiverse to move from target identification to functional antibodies?
The company's technology enables the rapid development of antibodies, typically progressing from initial target identification to functional lead candidates in approximately six months or less.
How does Antiverse use the 'Lab in a Loop' approach in its workflow?
This strategy involves an iterative cycle where generative AI models design antibody libraries, which are then built and tested in a wet lab to provide real-world data that further trains and improves the predictive accuracy of the models.
Does Antiverse collaborate with external pharmaceutical companies?
Yes, the company collaborates with several top global pharmaceutical firms and research foundations to advance antibody discovery programs and explore high-value disease targets.
What specific technologies does Antiverse combine to discover new therapeutics?
The platform integrates generative artificial intelligence and machine learning with advanced cell-line engineering and structural biology to accurately predict and validate antibody-antigen binding interactions.